In Vitro Diagnostics Market Size to be Worth $150.13 Billion by 2030 at CAGR 5.62%
SAN FRANCISCO, May 7, 2025 /PRNewswire/ -- The global in vitro diagnostics market size is expected to reach USD 150.13 billion in 2030 and is projected to grow at a CAGR of 5.62% from 2025 to 2030. driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.
Grand_View_Research_Logo
These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.
Request a free sample copy or view report summary: In Vitro Diagnostics Market
In Vitro Diagnostics Market Report Highlights:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
USANA Philippines Receives Two AP Stevie Awards
Company recognized for excellence in marketing and sustainability MANILA, Philippines, June 11, 2025 /PRNewswire/ -- USANA Philippines, a leader in health and wellness, has recently been recognized with two silver awards at the recent Asia Pacific Stevie Awards (AP Stevies). The awards highlight USANA's commitment to innovation, sustainability, and excellence. The AP Stevie Awards are widely considered to be one of the world's premier business awards, recognizing innovation in the workplace in all 29 nations of the Asia-Pacific region. "We are immensely proud to receive these prestigious awards, which are a testament to USANA's unwavering commitment to innovation, sustainability, excellence, and most importantly, our customers," said Cherry Ampig, USANA Philippines general manager. "These recognitions not only validate our efforts, but also motivate us to take that next step and do even more for our customers and the global USANA family." To learn more about USANA, please visit here. USANA Philippines won silver in the Innovation in Content Marketing/Branded Editorial category for its efforts in transforming its marketing department and creating content like their "Good Morning, USANA" show, doctor-centric content, user-generated content and challenges, and Viber and direct messaging campaigns. All of these strategies help position USANA as a pillar in the industry and create significant engagement with customers. USANA Philippines also won in the Innovation in Sustainability category for its recent sustainability initiatives. Last year, the market created a campaign to help recycle discarded plastic product bottles used by employees and customers. Approximately 8,000 kilos of plastic bottles were collected and then turned into 200 plastic chairs that were donated to a local school. USANA Philippines also led a service trip on Malapascua Island where they planted USANA Garden Towers to provide a sustainable source of nutritious food to those in the area. Each Garden Tower is made of durable material, can hold up to 120 plants, and uses 30% less water. About USANAUSANA (NYSE:USNA) prides itself in providing consumers nutritional products around the world. From its award-winning supplements to its innovative Celavive skincare and Active Nutrition lines, USANA has proven for over 30 years why it's a company you can trust. How about giving us a try? Shop at or learn more at Media Contact: +1 (801) 954-7645 media(at)USANAinc(dot)com View original content: SOURCE USANA
Miami Herald
15 minutes ago
- Miami Herald
Meta commits absurd money to top Google, Microsoft in critical race
Apparently, Meta Platforms (META) CEO Mark Zuckerberg has been up to more than just making the rounds on the podcast circuit. In recent months, the man behind the company that runs Facebook, Instagram, WhatsApp, Facebook Messenger, and Oculus has been on seemingly every manosphere podcast out there. Related: Facebook (Meta) makes a big deal with UFC In May, he debuted yet another new look on This Past Weekend with Theo Von, where he talked about how college doesn't do a good job of preparing people for their careers. In January, he appeared on The Joe Rogan Experience to speak about online censorship, the Covid vaccine, bots on Facebook, and encrypted messaging, among other things. More recently, he spoke with Ben Thompson of Stratechery about AI and where he sees social media going in the future. More on Meta: Meta (Facebook) shocks retail world with unexpected newsMeta quietly plans rude awakening for employees after layoffsSurprising earnings send Meta Platforms stock soaring While the interviews are great at increasing Zuckerberg's profile, they don't do much to move the needle for investors looking for Meta to debut its next big thing. For years, Zuckerberg's focus was the metaverse, but after tens of billions of dollars and years of development, the project hasn't gained the user base Meta was hoping for. Meta's Horizon Worlds virtual social platform had less than 200,000 monthly active users shortly after its launch in 2022, well short of the company's expectations of 500,000 users. Meta has shifted its focus to AI growth in recent years, and on Tuesday, a new report shows just how serious the company has become about topping its rivals. Mark Zuckerberg is applying the same focus he brought to building the metaverse to building out Meta's artificial intelligence capabilities. Zuckerberg is personally overseeing the creation of a "superintelligence" team, and the company is offering nine-figure compensation packages to attract top talent, according to a Bloomberg report. He believes Meta can beat competitors like Microsoft, Google, and OpenAI to achieve artificial general intelligence. AGI is the theoretical limit of what AI can achieve - machines performing tasks as well as, or better than, humans. Related: Gig work CEO warns of scary future for job seekers Bloomberg reported that the superteam will feature about 50 people, most of whom Zuckerberg will recruit personally. He's arranged the desks at the company's headquarters so the new staff will sit near him. The team is only one aspect of Meta's AGI strategy. According to a report in The Information on Tuesday, Meta is close to finalizing a $15 billion investment in Scale AI. If completed, the deal would become the company's largest-ever acquisition. Scale AI provides training data to everyone from Microsoft to Google to OpenAI. The investment would give Meta a 49% stake in the company, and CEO Alesandr Wang would join the superteam. The push for artificial intelligence that can perform tasks as well as or better than humans will inevitably lead to societal upheaval. The most immediate concern is about the jobs that will be lost to automation. When big companies like Meta and Alphabet want to save on costs, headcount is often one of the first places they look. Meta is currently laying off about 3,600 employees, whom the company says are underperforming. The company says it is eliminating redundancies, and it's true the tech sector went on a hiring spree during the pandemic. Now, however, it is replacing many of those positions with machine learning engineers. Machine learning is a subset of artificial intelligence focused on enabling machines to learn from data without explicit programming from humans. In other words, Meta has been laying off workers to hire other workers to build products, which will eventually lead to more layoffs. Related: Meta turns to powerful ally in battle against Europe The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
22 minutes ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@
